Cefazolin potency against methicillin-resistant *Staphylococcus aureus*: a microbiologic assessment in support of a novel drug delivery system for skin and skin structure infections

David P Nicolau 1
Barry N Silberg 2

1 Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA; 2 Department of Surgery, Sonoma West Medical Center, Sebastopol, CT, USA

**Introduction:** Despite aggressive medical and surgical management, the resolution of skin and skin structure infections is often difficult due to insufficient host response, reduced drug penetration, and a high prevalence of resistance organisms such as methicillin-resistant *Staphylococcus aureus* (MRSA). As a result of these factors, conventional management often consists of prolonged broad-spectrum systemic antimicrobials. An alternative therapy in development, ultrasonic drug dispersion (UDD), uses a subcutaneous injection followed by external transcutaneous ultrasound to deliver high tissue concentrations of cefazolin with limited systemic exposure. While it is postulated that these high concentrations may be suitable to treat more resistant organisms such as MRSA, the cefazolin minimum inhibitory concentration (MIC) distribution for this organism is currently unknown.

**Materials and methods:** We assessed the potency of cefazolin against a collection of 1,239 MRSA from 42 US hospitals using Clinical Laboratory Standard Institute-defined broth microdilution methodology.

**Results:** The cefazolin MIC inhibiting 50% of the isolates was 64 mg/L; 81% had MICs ≤ 128 and nearly all (99.9%) had MICs ≤ 512 mg/L.

**Conclusion:** The overwhelming majority of MRSA had cefazolin MICs that were considerably lower than achievable tissue concentrations (≥ 1,000 mg/L) using this novel drug delivery system. While the currently defined cefazolin MRSA phenotypic profile precludes the use of parenteral administration, techniques that deliver local exposures in excess of these inhibitory concentrations may provide a novel treatment strategy for skin and skin structure infections.

**Keywords:** methicillin-resistant, *Staphylococcus aureus*, ultrasonic, infection, cefazolin

**Introduction**

Although the treatment paradigm for skin and skin structure infections (SSSIs) in diabetics and those with peripheral vascular disease frequently incorporates aggressive medical and surgical interventions, infection resolution in these patient populations is often difficult due to insufficient host response, reduced drug penetration, and a high prevalence of resistance organisms such as methicillin-resistant *Staphylococcus aureus* (MRSA). 1 As a result of these factors, conventional medical management of these patients consists of the use of prolonged courses of broad-spectrum systemic antimicrobials. 2 Despite the administration of systemic antimicrobials, this approach often results in poor infection outcomes and the need for amputation. 3 Moreover, these currently utilized, prolonged antimicrobial regimens, unfortunately, also put patients at
risk for adverse events such as superinfections (ie, infection with a new pathogen in the previously infected wound or at a previously uninfected site such as *Clostridium difficile* diarrhea) and/or the development of resistance in the originally infecting organism(s).

In an attempt to provide high local antimicrobial concentrations and avoid unnecessary systemic exposures, novel drug delivery techniques are being investigated. However, before the viability of these delivery systems can be fully understood, an assessment of the potency of the test agent must be undertaken against the target organism(s) of interest. Due to its longstanding use for prophylaxis and infection treatment, good systemic safety profile over a wide range of doses, and the ability to use intramuscular administration without local tissue damage, cefazolin possesses suitable characteristics for consideration of direct drug delivery to the infection site.3,4 While the intravenous administration of cefazolin is commonly given for both surgical prophylaxis and treatment of Gram-positive organisms such as methicillin-susceptible *Staphylococcus aureus* (MSSA), due to the attainment of sufficiently high tissue concentrations which are in excess of typical MSSA minimum inhibitory concentrations (MICs) of 1–2 mg/L, achievable concentration using this route is considered too low for MRSA.5–7 Thus when considering the intravenous route of administration, organisms such as MRSA are considered intrinsically resistant to cefazolin. However, since this definition of resistance is based on achievable concentrations at the site of infection, if sufficiently high concentrations of an antimicrobial could be delivered in excess of the MIC using alternative drug delivery techniques, clinical efficacy may be recognized despite the classical definition of resistance based solely on the serum profile of the agent.

In an attempt to assess the utility of cefazolin for inclusion in a novel drug delivery system targeting skin infections, the activity of this compound against MRSA, one of the most frequently isolated and drug-resistant pathogens, would need to be determined in contemporary clinical isolates. Thus, the purpose of this study was to examine the in vitro microbiologic potency of cefazolin against large collection of MRSA derived from US hospitals.

**Materials and methods**

The MRSA included in the current investigation were collected between 2011 and 2013 from 42 US medical centers as part of a national surveillance program.7 All consecutive, non-duplicate organisms were identified by the local laboratory collecting the isolates, and reconfirmation of MRSA status was undertaken using BBL CHROMagar MRSA (BD, Franklin Lakes, NJ, USA) at the Center for Anti-Infective Research and Development (CAIRD), Hartford Hospital.

Susceptibility testing was conducted at the CAIRD using reference broth microdilution techniques according to guidelines published by the Clinical and Laboratory Standards Institute.8,9 ATCC *S. aureus* 29213 was used for quality control on all MIC trays prior to and during the conduct of susceptibility testing. Colony counts were performed on each isolate to verify whether the correct inoculum was delivered to the MIC tray. As a result of the high achievable cefazolin concentrations with the ultrasonic drug dispersion (UDD) technique, the MIC range against cefazolin was extended up to a concentration of 1,024 mg/L.

**Results**

A total of 1,239 MRSA were tested against cefazolin and the MIC inhibiting 50% and 90% of the isolates was 64 and 256 mg/L, respectively. Eighty-one percent of these isolates had MICs ≤128 mg/L and 5% had an MIC=512 mg/L. Only one isolate was noted to have an MIC of 1,024 mg/L. The MIC distribution for cefazolin against the MRSA population is displayed in Figure 1.

**Discussion**

Owing to the increasing compromise of the host and the prevalence of methicillin resistance among *S. aureus*, SSSIs have become one of the most challenging medical problems encountered in clinical arena.10 When considering this target pathogen, the increasing incidence of MRSA across the healthcare continuum has resulted in increased outpatient failures and higher rates of hospitalization for parental antimicrobials.10 In addition to the collective clinical implications, poor outcomes, and the need for frequent surgical intervention, the high prevalence of this disease entity represents an enormous cost of care liability to the
In the current study, we assessed the potency of cefazolin against a population of MRSA that had previously displayed typical phenotypic profiles to vancomycin, ceftriaxone, daptomycin, linezolid, and tigecycline. When the 1,239 MRSA were tested against cefazolin, 99.9% of these organisms had MICs ≤512 mg/L. Moreover, most of the isolates had cefazolin MIC values that were considerably lower than 256 mg/L. As a result of these contemporary potency data, it appears that achievable tissue concentrations of cefazolin with the UDD technique are well in excess of the concentrations required to inhibit the growth of MRSA.

Conclusion

While systemic cefazolin is not considered a viable therapeutic option for MRSA-related SSSIs because of its relatively low tissue concentrations in the face of the high MICs as presented in this current study, local drug delivery techniques appear to represent a novel strategy to achieve sufficiently high cefazolin concentrations in excess of its MRSA MIC profile. Ultimately, clinical trial data will be required to support or refute the utility of cefazolin administered via the UDD technique for the management of MRSA skin infections; however, until these data are available, studies such as this which define potency relative to achievable drug concentrations at the site of infection provide important insights for the clinical development process of this novel therapeutic intervention.

Acknowledgments

The authors thank Christina Sutherland and the staff of the Center for Anti-Infecctive Research and Development, Hartford Hospital, for conducting the in vitro susceptibility testing. Abstract of this paper has been presented: Nicolau DP, Silberg BN. Assessing the Potency of Cefazolin against Methicillin-Resistance Staphylococcus aureus (MRSA): Microbiologic Data Supporting Ultrasonic Drug Dispersion for the Management of Skin & Skin Structure Infections (SSSIs) (Abstract No. C-1071). 55th Interscience Conference on Antimicrobial Agents and Chemotherapy/International Congress of Chemotherapy and Infection, San Diego, CA, September 2015.

Author contributions

David P Nicolau and Barry N Silberg conceived and designed the experiments, reviewed the raw data and quality control procedures, analyzed the data, and wrote the paper.

Disclosure

Drs Nicolau and Silberg are shareholders in Sonescence, the developer of the UDD technique. The authors report no other conflicts of interest in this work.

References


